Literature DB >> 28451626

Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD.

Frederike C Oertel1, Hanna Zimmermann1, Janine Mikolajczak1, Maria Weinhold1, Ella Maria Kadas1, Timm Oberwahrenbrock1, Florence Pache1, Judith Bellmann-Strobl1, Klemens Ruprecht1, Friedemann Paul1, Alexander U Brandt1.   

Abstract

Entities:  

Year:  2017        PMID: 28451626      PMCID: PMC5398419          DOI: 10.1212/NXI.0000000000000338

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


× No keyword cloud information.
Neuromyelitis optica spectrum disorders (NMOSDs) are relapsing inflammatory demyelinating disorders with optic neuritis (ON) as the hallmark. ON causes neuroaxonal damage to the optic nerve and retina, regularly leading to severely impaired visual acuity (VA).[1] Peripapillary retinal nerve fiber layer (pRNFL) thickness measured by optical coherence tomography (OCT) has been increasingly recognized as a marker for neuroaxonal damage and correlate of visual dysfunction.[1] As such, pRNFL is implemented as an outcome in clinical trials of ON-associated disorders. Blood vessels (BVs) running within the pRNFL contribute approximately 13% to an average RNFL thickness[2] and could present an important confounder when tracking small pRNFL changes or in diseases with severe thinning such as NMOSD.[1] Against this background, the objective of this study was to investigate the influence of retinal BVs on pRNFL measurements in an NMOSD cohort.

Methods.

Forty patients from a prospective observational cohort study at the NCRC at Charité–Universitätsmedizin Berlin were enrolled (women/men: 39/1, age: 44.7 ± 15.4 years, 42 ON eyes). Inclusion criteria were a minimum age of 18 years and diagnosis of NMOSD according to the 2015 IPND criteria[3] (n = 37, aquaporin-4 antibody seropositive n = 28) or myelin oligodendrocyte glycoprotein-IgG–associated encephalomyelitis (n = 3).[4] Exclusion criteria were any other diseases which could influence OCT results. All patients were examined with a Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germany) using automatic real time (ART) function for image averaging. pRNFL was measured with a 3.4 mm ring scan around the optic nerve head (12°, 1536 A scans 16 ≤ ART ≤ 100) and segmented semiautomatically (Eye Explorer 1.9.10.0 with viewing module 6.0.9.0) and manually corrected by an experienced grader. BV positions were automatically detected by OCTSEG[5] (figure, A and B) and manually corrected. Three eyes were excluded because of insufficient image quality based on OSCAR-IB criteria.
Figure

Contribution of blood vessels to retinal nerve fiber layer thickness

(A) pRNFL scanned by optical coherence tomography, segmented with vessel detection. (B) Mean pRNFL thickness in μm; all regions including vessels and only regions without vessels. (C) Correlation of the relative blood vessel contribution to the pRNFL including vessels. pRNFL = peripapillary retinal nerve fiber layer.

Contribution of blood vessels to retinal nerve fiber layer thickness

(A) pRNFL scanned by optical coherence tomography, segmented with vessel detection. (B) Mean pRNFL thickness in μm; all regions including vessels and only regions without vessels. (C) Correlation of the relative blood vessel contribution to the pRNFL including vessels. pRNFL = peripapillary retinal nerve fiber layer. High-contrast VA was examined monocularly under habitual correction and photopic conditions with ETDRS charts at a simulated 20 ft distance using the Optec 6500 P System (Stereo Optical, Chicago, IL). pRNFL without vessels was calculated as mean thickness of all ring scan positions not marked as part of vessels and was compared with pRNFL with vessels using paired t tests. We performed Pearson correlation analyses for evaluation of the relationship between pRNFL and VA and Fisher z test for correlation comparison. The relative BV contribution in percentage was calculated as ([pRNFLwith vessels − pRNFLwithout vessels]/pRNFLwith vessels × 100%). All statistical tests were performed using R 3.1 with significance established at p < 0.05. The study was approved by the local Ethics Committee at Charité–Universitätsmedizin Berlin and was conducted in accordance with the Declaration of Helsinki.

Results.

pRNFL measurements were thinner without including BVs (76.1 ± 26.6 μm with, 68.3 ± 26.2 μm without, p < 2e−16; figure, C). Relative BV contribution increased with lower pRNFL (r = −0.700, p = 1e−12) (figure, D). When only considering eyes with pRNFL thickness below 60 μm, the mean relative BV contribution was significantly higher with 16% ± 5% compared with 9% ± 3% in eyes with RNFL >60 μm (p = 8e−8). VA (36 ± 19 ETDRS letters) was associated with pRNFL including BV (r = 0.621, p = 2e−9) and without BV (r = 0.618, p = 2e−9). In eyes with pRNFL measurements below 60 μm, pRNFL-VA correlation was numerically higher for pRNFL excluding BV (r = 0.495, p = 0.007) than pRNFL including BV (r = 0.482, p = 0.009), but the difference was not significant (p = 0.476). There were no influences of antibody status, disease duration and therapy on pRNFL, relative BV contribution, or enlargement of BV areas with pRNFL thinning (data not shown).[6]

Discussion.

BV contribution to average pRNFL measurements is higher in thin compared with normal/high pRNFL measurements. A previous study reported an average BV contribution of 13% to pRNFL measurements.[2] Our study expands these findings by showing that BV contribution is increased in low pRNFL measurements like the ones regularly found in NMOSD patients with severe ON. A relevant contribution of BV artifacts to measurement noise has been reported.[7] Although our results did not show a structure-function correlation improvement for vessel-corrected measurements, they suggest a downgrade in pRNFL measurement sensitivity. In NMOSD cohorts, a wide range of pRNFL thickness measurements are seen, including those lower than 60 μm.[1] Typically, pRNFL differences of only a few micrometers are used to evaluate drug efficacy in ON trials.[8] Thus, in longitudinal studies, vessel artifacts potentially interfere with the comparability of an absolute thickness change because the relative vessel contribution increases with thinner pRNFL. We propose analyzing OCT data in studies including NMOSD and other conditions with low pRNFL measurements in addition to vessel correction. Further studies of retrospective and prospective data and larger cohorts are required to confirm and specify BV influence and to identify reliable surrogates for tracking ON-related damage in NMOSD.
  8 in total

1.  Retinal hyperaemia-related blood vessel artifacts are relevant to automated OCT layer segmentation.

Authors:  L J Balk; M Mayer; B M J Uitdehaag; A Petzold
Journal:  J Neurol       Date:  2014-01-05       Impact factor: 4.849

2.  Blood vessel contributions to retinal nerve fiber layer thickness profiles measured with optical coherence tomography.

Authors:  Donald C Hood; Brad Fortune; Stella N Arthur; Danli Xing; Jennifer A Salant; Robert Ritch; Jeffrey M Liebmann
Journal:  J Glaucoma       Date:  2008 Oct-Nov       Impact factor: 2.503

3.  A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.

Authors:  Kurt-Wolfram Sühs; Katharina Hein; Muriel B Sättler; Anke Görlitz; Christoph Ciupka; Kerstin Scholz; Barbara Käsmann-Kellner; Panagiotis Papanagiotou; Nina Schäffler; Cordula Restemeyer; Diana Bittersohl; Andrea Hassenstein; Berthold Seitz; Wolfgang Reith; Klaus Fassbender; Reinhard Hilgers; Christoph Heesen; Mathias Bähr; Ricarda Diem
Journal:  Ann Neurol       Date:  2012-08       Impact factor: 10.422

4.  Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis.

Authors:  A J Green; B A C Cree
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-05-21       Impact factor: 10.154

5.  Retinal Nerve Fiber Layer Segmentation on FD-OCT Scans of Normal Subjects and Glaucoma Patients.

Authors:  Markus A Mayer; Joachim Hornegger; Christian Y Mardin; Ralf P Tornow
Journal:  Biomed Opt Express       Date:  2010-11-08       Impact factor: 3.732

Review 6.  Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.

Authors:  J L Bennett; J de Seze; M Lana-Peixoto; J Palace; A Waldman; S Schippling; S Tenembaum; B Banwell; B Greenberg; M Levy; K Fujihara; K H Chan; H J Kim; N Asgari; D K Sato; A Saiz; J Wuerfel; H Zimmermann; A Green; P Villoslada; F Paul
Journal:  Mult Scler       Date:  2015-02-06       Impact factor: 6.312

7.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

8.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.

Authors:  Florence Pache; Hanna Zimmermann; Janine Mikolajczak; Sophie Schumacher; Anna Lacheta; Frederike C Oertel; Judith Bellmann-Strobl; Sven Jarius; Brigitte Wildemann; Markus Reindl; Amy Waldman; Kerstin Soelberg; Nasrin Asgari; Marius Ringelstein; Orhan Aktas; Nikolai Gross; Mathias Buttmann; Thomas Ach; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt
Journal:  J Neuroinflammation       Date:  2016-11-01       Impact factor: 8.322

  8 in total
  6 in total

1.  Active contour method for ILM segmentation in ONH volume scans in retinal OCT.

Authors:  Kay Gawlik; Frank Hausser; Friedemann Paul; Alexander U Brandt; Ella Maria Kadas
Journal:  Biomed Opt Express       Date:  2018-11-28       Impact factor: 3.732

2.  CuBe: parametric modeling of 3D foveal shape using cubic Bézier.

Authors:  Sunil Kumar Yadav; Seyedamirhosein Motamedi; Timm Oberwahrenbrock; Frederike Cosima Oertel; Konrad Polthier; Friedemann Paul; Ella Maria Kadas; Alexander U Brandt
Journal:  Biomed Opt Express       Date:  2017-08-22       Impact factor: 3.732

Review 3.  [Optical coherence tomography in neuromyelitis optica spectrum disorders].

Authors:  F C Oertel; H Zimmermann; A U Brandt; F Paul
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

Review 4.  Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.

Authors:  Frederike C Oertel; Hanna Zimmermann; Friedemann Paul; Alexander U Brandt
Journal:  EPMA J       Date:  2017-12-22       Impact factor: 6.543

Review 5.  Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.

Authors:  Nadja Borisow; Masahiro Mori; Satoshi Kuwabara; Michael Scheel; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-23       Impact factor: 4.003

6.  Optical coherence tomography angiography helps distinguish multiple sclerosis from AQP4-IgG-seropositive neuromyelitis optica spectrum disorder.

Authors:  Chunxin Liu; Hui Xiao; Xiayin Zhang; Yipeng Zhao; Rui Li; Xiaonan Zhong; Yuge Wang; Yaqing Shu; Yanyu Chang; Jingqi Wang; Caixia Li; Haotian Lin; Wei Qiu
Journal:  Brain Behav       Date:  2021-03-30       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.